FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194293108> ?p ?o ?g. }

• W3194293108 endingPage "e657" @default.
• W3194293108 startingPage "e648" @default.
• W3194293108 abstract "Background Autologous haematopoietic stem-cell transplantation (HSCT) in first remission is the current standard treatment in fit patients with mantle cell lymphoma. In this long-term follow-up study, we aimed to evaluate the efficacy of autologous HSCT versus interferon alfa maintenance after chemotherapy without or with rituximab in patients with primary advanced-stage mantle cell lymphoma. Methods We did a post-hoc, long-term analysis of an open-label, multicentre, randomised, phase 3 trial done in 121 participating hospitals or practices across six European countries. Patients who were aged 18–65 years with previously untreated stage III–IV mantle cell lymphoma and an ECOG performance score of 0–2 were eligible for participation. Patients were randomly assigned (1:1) to receive either myeloablative radiochemotherapy (fractionated total body irradiation with 12 Gy/day 6–4 days before autologous HSCT and cyclophosphamide 60 mg/kg per day intravenously 3–2 days before autologous HSCT) followed by autologous HSCT (the autologous HSCT group) or interferon alfa maintenance (the interferon alfa maintenance group; 6 × 106 IU three times a week subcutaneously until progression) after completion of CHOP-like induction therapy (cyclophosphamide 750 mg/m2 intravenously on day 1, doxorubicin 50 mg/m2 intravenously on day 1, vincristine 1·4 mg/m2 [maximum 2 mg] intravenously on day 1, and prednisone 100 mg/m2 orally on days 1–5; repeated every 21 days for up to 6 cycles) without or with rituximab (375 mg/m2 intravenously on day 0 or 1 of each cycle; R-CHOP). The primary outcome was progression-free survival from end of induction until progression or death among patients who had a remission and the secondary outcome was overall survival from the end of induction until death from any cause. We did comparisons of progression-free survival and overall survival according to the intention-to-treat principle between both groups among responding patients and explored efficacy in subgroups according to induction treatment without or with rituximab. Hazard ratios (HRs) were adjusted for the mantle cell lymphoma international prognostic index (MIPI) numerical score, and in the total group also for rituximab use (adjusted HR [aHR]). This trial was started before preregistration was implemented and is therefore not registered, recruitment is closed, and this is the final evaluation. Findings Between Sept 30, 1996, and July 1, 2004, 269 patients were randomly assigned to receive either autologous HSCT or interferon alfa maintenance therapy. The median follow-up was 14 years (IQR 10–16), with the intention-to-treat population consisting of 174 patients (93 [53%] in the autologous HSCT group and 81 [47%] in the interferon alfa maintenance group) who responded to induction therapy. The median age was 55 years (IQR 47–60), and R-CHOP was used in 68 (39%) of 174 patients. The median progression-free survival was 3·3 years (95% CI 2·5–4·3) in the autologous HSCT group versus 1·5 years (1·2–2·0) in the interferon alfa maintenance group (log-rank p<0·0001; aHR 0·50 [95% CI 0·36–0·69]). The median overall survival was 7·5 years (95% CI 5·7–12·0) in the autologous HSCT group versus 4·8 years (4·0–6·6) in the interferon alfa maintenance group (log-rank p=0·019; aHR 0·66 [95% CI 0·46–0·95]). For patients treated without rituximab, the progression-free survival adjusted HR for autologous HSCT versus interferon alfa was 0·40 (0·26–0·61), in comparison to 0·72 (0·42–1·24) for patients treated with rituximab. For overall survival, the adjusted hazard ratio for HSCT versus interferon alfa was 0·52 (0·33–0·82) without rituximab and 1·05 (0·55–1·99) for patients who received rituximab. Interpretation Our results confirm the long-term efficacy of autologous HSCT to treat mantle cell lymphoma established in the pre-rituximab era. The suggested reduced efficacy after immunochemotherapy supports the need for its re-evaluation now that antibody maintenance, high-dose cytarabine, and targeted treatments have changed the standard of care for patients with mantle cell lymphoma. Funding Deutsche Krebshilfe, the European Community, and the Bundesministerium für Bildung und Forschung, Kompetenznetz Maligne Lymphome." @default.
• W3194293108 created "2021-08-30" @default.
• W3194293108 creator A5001222821 @default.
• W3194293108 creator A5005029408 @default.
• W3194293108 creator A5009186146 @default.
• W3194293108 creator A5011643510 @default.
• W3194293108 creator A5012101254 @default.
• W3194293108 creator A5019866348 @default.
• W3194293108 creator A5020375942 @default.
• W3194293108 creator A5027857526 @default.
• W3194293108 creator A5033073385 @default.
• W3194293108 creator A5033079310 @default.
• W3194293108 creator A5033935778 @default.
• W3194293108 creator A5036867361 @default.
• W3194293108 creator A5039142430 @default.
• W3194293108 creator A5042951988 @default.
• W3194293108 creator A5046049357 @default.
• W3194293108 creator A5053099326 @default.
• W3194293108 creator A5053239525 @default.
• W3194293108 creator A5071753657 @default.
• W3194293108 creator A5077504536 @default.
• W3194293108 creator A5084791226 @default.
• W3194293108 creator A5088691613 @default.
• W3194293108 creator A5090442302 @default.
• W3194293108 date "2021-09-01" @default.
• W3194293108 modified "2023-09-28" @default.
• W3194293108 title "Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial" @default.
• W3194293108 cites W1912693401 @default.
• W3194293108 cites W1972715557 @default.
• W3194293108 cites W2010523573 @default.
• W3194293108 cites W2026122699 @default.
• W3194293108 cites W2059492063 @default.
• W3194293108 cites W2099700439 @default.
• W3194293108 cites W2124235514 @default.
• W3194293108 cites W2124432094 @default.
• W3194293108 cites W2130669641 @default.
• W3194293108 cites W2151092645 @default.
• W3194293108 cites W2153569820 @default.
• W3194293108 cites W2162109567 @default.
• W3194293108 cites W2163790170 @default.
• W3194293108 cites W2190884983 @default.
• W3194293108 cites W2327039910 @default.
• W3194293108 cites W2430862255 @default.
• W3194293108 cites W2760635695 @default.
• W3194293108 cites W2887303306 @default.
• W3194293108 cites W2906765096 @default.
• W3194293108 cites W4205736005 @default.
• W3194293108 cites W4211030010 @default.
• W3194293108 doi "https://doi.org/10.1016/s2352-3026(21)00195-2" @default.
• W3194293108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34450102" @default.
• W3194293108 hasPublicationYear "2021" @default.
• W3194293108 type Work @default.
• W3194293108 sameAs 3194293108 @default.
• W3194293108 citedByCount "22" @default.
• W3194293108 countsByYear W31942931082021 @default.
• W3194293108 countsByYear W31942931082022 @default.
• W3194293108 countsByYear W31942931082023 @default.
• W3194293108 crossrefType "journal-article" @default.
• W3194293108 hasAuthorship W3194293108A5001222821 @default.
• W3194293108 hasAuthorship W3194293108A5005029408 @default.
• W3194293108 hasAuthorship W3194293108A5009186146 @default.
• W3194293108 hasAuthorship W3194293108A5011643510 @default.
• W3194293108 hasAuthorship W3194293108A5012101254 @default.
• W3194293108 hasAuthorship W3194293108A5019866348 @default.
• W3194293108 hasAuthorship W3194293108A5020375942 @default.
• W3194293108 hasAuthorship W3194293108A5027857526 @default.
• W3194293108 hasAuthorship W3194293108A5033073385 @default.
• W3194293108 hasAuthorship W3194293108A5033079310 @default.
• W3194293108 hasAuthorship W3194293108A5033935778 @default.
• W3194293108 hasAuthorship W3194293108A5036867361 @default.
• W3194293108 hasAuthorship W3194293108A5039142430 @default.
• W3194293108 hasAuthorship W3194293108A5042951988 @default.
• W3194293108 hasAuthorship W3194293108A5046049357 @default.
• W3194293108 hasAuthorship W3194293108A5053099326 @default.
• W3194293108 hasAuthorship W3194293108A5053239525 @default.
• W3194293108 hasAuthorship W3194293108A5071753657 @default.
• W3194293108 hasAuthorship W3194293108A5077504536 @default.
• W3194293108 hasAuthorship W3194293108A5084791226 @default.
• W3194293108 hasAuthorship W3194293108A5088691613 @default.
• W3194293108 hasAuthorship W3194293108A5090442302 @default.
• W3194293108 hasBestOaLocation W31942931082 @default.
• W3194293108 hasConcept C126322002 @default.
• W3194293108 hasConcept C141071460 @default.
• W3194293108 hasConcept C2776694085 @default.
• W3194293108 hasConcept C2776755627 @default.
• W3194293108 hasConcept C2777408962 @default.
• W3194293108 hasConcept C2777525834 @default.
• W3194293108 hasConcept C2779050716 @default.
• W3194293108 hasConcept C2779338263 @default.
• W3194293108 hasConcept C2779429289 @default.
• W3194293108 hasConcept C2779725641 @default.
• W3194293108 hasConcept C2780653079 @default.
• W3194293108 hasConcept C2911091166 @default.
• W3194293108 hasConcept C71924100 @default.
• W3194293108 hasConcept C90924648 @default.
• W3194293108 hasConceptScore W3194293108C126322002 @default.
• W3194293108 hasConceptScore W3194293108C141071460 @default.
• W3194293108 hasConceptScore W3194293108C2776694085 @default.

• next